Navigation Links
Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
Date:5/21/2008

to what we predicted based on extensive lab testing of JX-594. This peer-reviewed publication in a Lancet journal represents a major advance for JX-594 and the rest of our pipeline," said David Kirn, M.D., President & CEO of Jennerex. "We especially want to express our extreme gratitude to the doctors, the patients and their families, and our partners at Green Cross who have all pioneered this treatment with us."

Dr. B. G. Rhee, Executive Vice President, Corporate Development at Green Cross, said "Based on these promising clinical results with our partners at Jennerex, we are in the process of opening the Phase II liver cancer trial at world-renowned liver cancer hospitals in South Korea." Jennerex collaborated closely with medical and scientific research teams in South Korea at Dong-A University and Pusan National University Hospitals, and at the Ottawa Health Research Institute, Ottawa, Canada.

Phase I-II Liver Cancer Study

As reported in the Lancet Oncology publication, 14 patients with a variety of treatment-refractory cancer types (e.g. liver, colon, lung) in the liver were treated every three weeks with JX-594 by ultrasound-guided intratumoral injection. Patients had advanced cancers that had failed all available therapies and were therefore considered terminal. Treatment was well-tolerated during dose-escalation up to the maximum-tolerated dose, with the expected mild to moderate flu-like symptoms; no severe toxicities due to treatment were reported up to these doses. Cancer destruction and objective evidence for efficacy were reported in the majority of patients, including all three with primary liver cancer and patients with lung and colon cancers. Tumor responses were achieved in evaluable patients by objective criteria including RECIST (Response Evaluation Criteria in Solid Tumor) (response in 30 percent of patients, stable disease in 60 percent of patients) and Choi criteria (response in 80% of patients). Tumor responses were associ
'/>"/>

SOURCE Jennerex
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
4. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
5. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
6. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
7. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
8. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
9. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
10. Promising Cystic Fibrosis Compound on Track for Development
11. Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  The Partnership to Fight Chronic Disease (PFCD) released ... care leaders and a new study analyzing the impact of increased ... a nationwide coalition working to educate policy makers and the public ... Capitol was focused on how the Iowa ...
(Date:1/23/2015)... Fla. and DUBLIN , Jan. ... the agreement with KRS Global Biotechnology, Inc. for the compounding, ... be compounded for shipment in the United States ... FDA approved Outsourcing Facility capable of compounding naltrexone tablets in ...
(Date:1/23/2015)... , Jan. 23, 2015  iMD Companies, Inc. (ICBU) has ... increase market share and grab a foothold in the hydroponic, ... production capabilities and a presence in the sector, and recently ... the growth of hemp and medical marijuana, iMD is committing ...
Breaking Medicine Technology:New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2
... , WILMINGTON, Del., Dec. 8 AstraZeneca (NYSE: ... Medicare Part D prescription savings program will no longer pay ... http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO ) , Prescriptions also now will ... changes to the AZ&Me(TM) Prescription Savings program for people with ...
... , PITTSBURGH, Dec. 8 Mylan Inc. (Nasdaq: ... has entered into settlement and license agreements with Wyeth, now ... (ER) Capsules, 37.5 mg, 75 mg and 150 mg, the ... major depressive disorder. , Pursuant to the license agreement, Mylan ...
Cached Medicine Technology:AstraZeneca Medicare Part D Patient Assistance Program No Longer Requires Co-Pays 2Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R) 2
(Date:1/22/2015)... a seasoned and trusted leader who consistently delivers trendy dresses ... it lead the wedding dress industry into the future. Today, ... the global market. , “The CEO of VogueQueen is uniquely ... continuing the goal of operational excellence and giving back to ...
(Date:1/22/2015)... 23, 2015 Angelweddingdress is a famous wedding ... its customers to follow it on Facebook, Twitter, and Pinterest. ... Day gift. Angelweddingdress draws a lottery every week. , Moreover, ... Feb. 28, 2015. Click Angelweddingdress homepage for more ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has ... View website of AngelWeddingDress.com to find more ... dresses online for a bridal party. AngelWeddingDress offers a ... them. Its maternity wedding dresses are specially designed for ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and ... Merchandise Show to bestow a Juvent Sports Achievement award ... Arlene McKitrick. The award commemorated and congratulated McKitrick for ... She won her first amateur tournament in 1979 and ...
(Date:1/22/2015)... 2015 Thousand of GranuFlo lawsuits ( ... its GranuFlo and NaturaLyte dialysis concentrates continue to move ... District Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... has remanded a case filed by the state of ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4
... MAY 28 Family Health International announced today that ... from the Bill & Melinda Gates Foundation. The ... led by David C. Sokal, M.D., studying a novel ... Sokal,s project is one of 81 grants announced by ...
... Identify Developmental Delays and Promote GrowthNEW ORLEANS, May 28 ... - 11:30am , at 1315 Jefferson Highway , ... "Reach Out and Read " with Louisiana,s First Lady ... program. In this initiative, pediatricians encourage parents to read ...
... with a terminal illness, African-American seniors were two times ... life-prolonging treatments, according to a University of Pittsburgh study ... the Journal of General Internal Medicine . ... M.P.H., associate professor of medical, clinical and translational science ...
... owned subsidiary of sanofi-aventis U.S. LLC, has agreed to pay ... violated the False Claims Act by misreporting drug prices in ... Department announced today. ... that between 1995 and 2000, Aventis and its corporate predecessors ...
... Public/Private Partnership Launches at State Legislative Hearing TRENTON, N.J., ... that could cause grave harm to patient care in ... New Jersey Chamber of Commerce Foundation today announced a ... will have the nursing workforce it needs to meet ...
... Kyowa Hakko U.S.A., Inc. (Kyowa Hakko USA), the wholly ... has announced it has completed GRAS (Generally Recognized As ... Citicoline. Cognizin(R) is a branded form of Citicoline, a ... Citicoline provides an essential nutrient for cells -- ...
Cached Medicine News:Health News:Family Health International Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research Project Led by David Sokal, M.D. 2Health News:Family Health International Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research Project Led by David Sokal, M.D. 3Health News:Family Health International Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research Project Led by David Sokal, M.D. 4Health News:Ochsner Introduces Literacy Program to Promote Healthy Minds 2Health News:Blacks more likely to opt for life-sustaining measures at end of life 2Health News:Aventis Pharmaceutical to Pay U.S. $95.5 Million to Settle False Claims Act Allegations 2Health News:$22 Million Initiative Aims to Reverse New Jersey's Nurse Faculty Shortage, Avert Health Care Crisis 2Health News:$22 Million Initiative Aims to Reverse New Jersey's Nurse Faculty Shortage, Avert Health Care Crisis 3Health News:$22 Million Initiative Aims to Reverse New Jersey's Nurse Faculty Shortage, Avert Health Care Crisis 4Health News:$22 Million Initiative Aims to Reverse New Jersey's Nurse Faculty Shortage, Avert Health Care Crisis 5Health News:Kyowa Hakko USA Announces GRAS Self-Affirmation for Novel Brain Health Ingredient Cognizin(R) Citicoline 2
Intended for the quantitative determination of glucose in serum. Reaction: endpoint. Wavelength: 500 nm. Linearity: 500 mg/dL (27.8 mmol/L)....
Inorganic phosphorus reagent is used for the quantitative determination of inorganic phosphorus in human serum....
For the quantitative kinetic determination of amylase activity, using manual or automated procedures, in human serum and urine....
Intended for the quantitative determination of gammaglutamyl transferase activity in serum or plasma. Single vial, dry powder reagent. Readily soluble at room temperature. Reaction: Kinetic. Waveleng...
Medicine Products: